Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 982-986

  Kanyok, Thomas P ^a   Killian, Aaron D ^a   Rodvold, Keith A ^a,b   Danziger, Larry H ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; PAROMOMYCIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031002038     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.982     Document Type: Article

References (30)

1. American Thoracic Society. 1992. Control of tuberculosis in the United States. Am. Rev. Respir. Dis. 146:1623-1633.
2. Arcamone, F., C. Bertazzoli, A. Buogo, G. Cassinelli, and A. Vigevani. 1974. New studies in the field of aminoglycosidic aminocyclitol antibiotics. Panminerva Med. 16:9-24.
3. Bloch, A. B., G. M. Cauthen, I. M. Onorato, K. G. Dansbury, G. D. Kelly, C. R. Driver, and D. E. Snider. 1994. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 271:665-671.
4. Centers for Disease Control. 1992. National action plan to combat multidrua-resistant tuberculosis. Morbid. Mortal. Weekly Rep. 41(RR-11):5-8.
5. Chunge, C. N., J. Owate, H. O. Pamba, and L. Donno. 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84:221-225.
6. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. Daikos, G. K., P. Komtomichalou, E. Petassis, and D. Bilalis. 1964. Clinical and laboratory experience with aminosidin, a broad-spectrum oligosaccharide antibiotic, p. 765-773. Antimicrob. Agents Chemother. 1963.
8. Fisher, M. W., M. C. Manning, L. A. Gagliardi, M. R. Gaetz, and A. L. Erlandson. 1959-60. Paromomycin: experimental antibacterial activity. Antibiot. Annu., p. 293-303.
9. Frieden, T. R., T. S. Sterling, A. Pablos-Mendez, J. O. Kilburn, G. M. Cauthen, and S. W. Dooley. 1993. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 328:521-526.
10. Goble, M., M. D. Iseman, L. A. Madsen, D. W. Waite, L. Ackerson, and R. Horsburgh, Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532.
11. Jereb, J. A., G. D. Kelly, S. W. Dooley, G. M. Cauthen, and D. E. Snider. 1991. Tuberculosis morbidity in the United States: final data, 1990. Morbid. Mortal. Weekly Rep. 40(SS-3):23-27.
12. Kanyok, T. P., M. Venkata Reddy, J. Chinnaswamy, L. H. Danziger, and P. R. J. Gangadharam. 1994. Activity of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J. Antimicrob. Chemother. 33:323-327.
13. Kanyok, T. P., M. Venkata Reddy, J. Chinnaswamy, L. H. Danziger, and P. R. J. Gangadharam. 1994. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob. Agents Chemother. 38:170-173.
14. Kirby, W. M., J. T. Clarke, R. D. Libke, and C. Regamey. 1976. Clinical pharmacology of amikacin and kanamycin. J. Infect. Dis. 134:S312-S330.
15. Kucers, A., and N. M. Bennett. 1987. The use of antibiotics, 4th ed., p. 739-745. J. B. Lippincott, Philadelphia, Pa.
16. Mariani, B., G. Velluti, and C. F. Marchioni. 1974. New therapeutic perspectives of aminosidine in pneumology. Panminerva Med. 16:376-390.
17. Mendelson, J., J. Portnoy, and H. Sigman. 1973. Pharmacology of gentamicin in the biliary tract of humans. Antimicrob. Agents Chemother. 4:538-541.
18. Metropolitan Life Foundation. 1983. Metropolitan height and weight tables. Stat. Bull. Metrop. Life Insur. Co. 64:1-9.
19. Novarini, A., A. Montanari, G. Bruschi, E. Rossi, A. Borghetti, and L. Migone. 1975. The kinetics of aminosidine in renal patients with different degrees of renal failure. Clin. Nephrol. 4:23-24.
20. Parke-Davis, Inc. 1986. Package insert. Paromomycin (Humatin), February. Parke-Davis, Pharmaceutical Research Division, Warner Lambert Co., Ann Arbor, Mich.
21. Pitt, H. A., R. B. Roberts, and W. D. Johnson, Jr. 1973. Gentamicin levels in the human biliary tract. J. Infect. Dis. 127:299.
22. Rimoldi, R., P. Perrotta, E. Morvillo, G. Schioppacassi, and L. Curcio. 1973. Aminosidine dosage in patients with normal and impaired renal function. Panminerva Med. 14:77-80.
23. Seaman, J., D. Pryce, H. E. Sondorp, A. Moody, A. D. M. Bryceson, and R. N. Davidson. 1993. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168:715-720.
24. Schentag, J. J., and W. J. Jusko. 1977. Renal clearance and tissue accumulation of gentamicin. Clin. Pharmacol. Ther. 22:364-370.
25. Schentag, J. J., W. J. Jusko, J. W. Vance, T. J. Cumbo, E. Abrutyn, M. DeLattre, and L. M. Gerbracht. 1977. Gentamicin disposition and tissue accumulation on multiple dosing. J. Pharmacokinet. Biopharm. 5:559-577.
26. Scott, J. A. G., R. N. Davidson, A. H. Moody, H. R. Grant, D. Felmingham, G. M. S. Scott, P. Olliaro, and A. D. M. Bryceson. 1992. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans. R. Soc. Trop. Med. Hyg. 86:617-619.
27. Telzak, E. E., K. Sepkowitz, P. Alpert, S. Mannheimer, F. Medard, W. El-Sadr, S. Blum, A. Gagliardi, N. Salomon, and G. Turett. 1995. Multi-drug resistant tuberculosis in patients without HIV infection. N. Engl. J. Med. 333:907-911.
28. Thakur, C. P., P. Olliaro, S. Gothoshar, Bhowmick, B. K. Choudhury, S. Prasad, M. Kumar, and B. B. Verma. 1992. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg. 86:615-616.
29. Turett, G. S., E. E. Telzak, L. V. Torian, S. Blum, D. Alland, I. Weisfuse, and B. A. Fazal. 1995. Improved outcomes in patients with multi-drug resistant tuberculosis. Clin. Infect. Dis. 21:1238-1244.
30. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.